Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-178.
Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007; 100: 987-1006.
Aizawa N, Igawa Y, Andersson KE, Iijima K, Nishizawa O, Wyndaele JJ. Effects of intravesical instillation of ATP on rat bladder primary afferent activity and its relationship with capsaicin-sensitivity. Neurourol Urodyn 2011; 30: 163-168.
Azadzoi KM. Effect of chronic ischemia on bladder structure and function. Adv Exp Med Biol 2003; 539: 271-280.
Azadzoi KM, Yalla SV, Siroky MB. Oxidative stress and neurodegeneration in the ischemic overactive bladder. J Urol 2007; 178: 710-715.
Berry SJ, Coffey DS, Walsh PC, Ewing LL The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-479.
Brading A, Pessina F, Esposito L, Symes S. Effects of metabolic stress and ischaemia on the bladder, and the relationship with bladder overactivity. Scand J Urol Nephrol Suppl 2004; 215: 84-92.
Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol. 1975; 47: 193-202.
Cavalli A, Lattion AL, Hummler E, Nenniger M, Pedrazzini T, Aubert JF, Michel MC, Yang M, Lembo G, Vecchione C, Mostardini M, Schmidt A, Beermann F, Cotecchia S. Decreased blood pressure response in mice deficient of the α1b-adrenergic receptor. Proc Natl Acad Sci USA 1997; 94: 11589-11594.
Chancellor MB, Rivas DA. American urological association symptom index for women with voiding symptoms: Lack of index specificity for benign prostatic hyperplasia. J Urol 1993; 150: 1706-1708.
Chapple C. Chapter 2: Pathophysiology of neurogenic detrusor overactivity and the symptom complex of “overactive bladder”. Neurourol Urodyn 2014; 33: S6-S13.
Chess-Williams R, Chapple CR, Verfurth F, Noble AJ, Couldwell CJ, Michel MC. The effects of SB 216469, an antagonist which discriminates between the α1A-adrenoceptor and the human prostatic α1-adrenoceptor. Br J Pharmacol 1996; 119: 1093-1100.
Coyne KS, Wein AJ, Tubaro A, Sexton CC, Thompson CL, Kopp ZS, Aiyer LP. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int 2009; 103 Suppl 3: 4-11.
Das AK, Leggett RE, Whitbeck C, Eagen G, Levin RM. Effect of doxazosin on rat urinary bladder function after partial outlet obstruction. Neurourol Urodyn 2002; 21: 160-166.
de Mey C, Michel MC, McEwen J, Moreland T. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol 1998; 33: 481-488.
Gibbons, EP., Colen, J., Nelson, JB. Benoit, RM. Correlation between risk factors for vascular disease and the American Urological Association Symptom Score. BJU Int 2007; 99: 97–100.
Greenland JE, Hvistendahl JJ, Andersen H, Jörgensen TM, McMurray G, Cortina-Borja M, Brading AF, Frøkiaer J. The effect of bladder outlet obstruction on tissue oxygen tension and blood flow in the pig bladder. BJU Int 2000; 85: 1109-1114.
Hara H, Ichikawa M, Oku H, Shimazawa M, Araie M. Bunazosin, a selective α1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev 2005; 23: 43-56.
Hashimoto T, Nagabukuro H, Doi T. Effects of the selective acetylcholinesterase inhibitor TAK802 on the voiding behavior and bladder mass increase in rats with partial bladder outlet obstruction. J Urol 2005; 174: 1137-1141.
Homma Y, Yamaguchi O, Hayashi K, the Members of the Neurogenic Bladder Society Committee. Epidemiologic survey of lower urinary tract symptoms in Japan. Urology 2006; 68: 560-564.
Ishihama H, Momota Y, Yanase H, Wang X, de Groat WC, Kawatani M. Activation of alpha1D adrenergic receptors in the rat urothelium facilitates the micturition reflex. J Urol 2006; 175: 358-364.
Kato K, Monson FC, Longhurst PA, Wein AJ, Haugaard N, Levin RM. The functional effects of long-term outlet obstruction on the rabbit urinary bladder. J Urol 1990; 143: 600-606.
Kenny BA, Miller AM, Williamson IJ, O'Connell J, Chalmers DH, Naylor AM. Evaluation of the pharmacological selectivity profile of α1 adrenoceptor antagonists at prostatic α1 adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol 1996; 118: 871-878.
Kwon SY, Lee KS, Yoo TK, Chung JI, Lee JY, Hong JH, Seo SI, Jung TY, Kwak C, Kang TW, Yun SJ. Comparison of the effect of naftopidil 75 mg and tamsulosin 0.2 mg on the bladder storage symptom with benign prostatic hyperplasia: Prospective, multi-institutional study. Urology 2018; 111: 145-150.
Lee SWH, Chan EMC, Lai YK. The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis. Sci Rep 2017; 7:Article 7984.
Lepor H, Machi G. Comparison of AUA symptom index in unselected males and females between fifty-five and seventy-nine years of age. Urology 1993; 42: 36-40.
Lin AT, Chen MT, Yang CH, Chang LS. Blood flow of the urinary bladder: effects of outlet obstruction and correlation with bioenergetic metabolism. Neurourol Urodyn 1995; 14: 285-292.
Martí D, Miquel R, Ziani K, Gisbert R, Ivorra MD, Anselmi E, Moreno L, Villagrasa V, Barettino D, D'Ocon P. Correlation between mRNA levels and functional role of α1- adrenoceptor subtypes in arteries: evidence of α1L as a functional isoform of the α1Aadrenoceptor. Am J Physiol Heart Circ Physiol 2005; 289: H1923-H1932.
Masuda H, Kihara K, Saito K, Matsuoka Y, Yoshida S, Chancellor MB, de Groat WC, Yoshimura N. Reactive oxygen species mediate detrusor overactivity via sensitization of afferent pathway in the bladder of anaesthetized rats. BJU Int. 2008; 101: 775-780.
Matsui T, Oka M, Fukui T, Tanaka M, Oyama T, Sagawa K, Nomiya M, Yamaguchi O. Suppression of bladder overactivity and oxidative stress by the phytotherapeutic agent, Eviprostat, in a rat model of atherosclerosis-induced chronic bladder ischemia. Int J Urol 2012; 19: 669–675.
Matsumoto S, Chichester P, Bratslavsky G, Kogan BA, Levin RM. The functional and structural response to distention of the rabbit whole bladder in vitro. J Urol 2002; 168: 2677-2681.
Matsumoto S, Chichester P, Kogan BA, Levin RM. Structural and vascular response of normal and obstructed rabbit whole bladders to distension. Urology 2003; 62: 1129-1133.
Mirone V, Imbimbo C, Longo N, Fusco F. The detrusor muscle: an innocent victim of bladder outlet obstruction. Eur Urol. 2007; 51: 57-66.
Mitterberger M, Pallwein L, Gradl J, Frauscher F, Neuwirt H, Leunhartsberger N, Strasser H, Bartsch G, Pinggera GM. Persistent detrusor overactivity after transurethral resection of the prostate is associated with reduced perfusion of the urinary bladder. BJU Int 2007; 99: 831- 835.
Mizuno H, Yamamoto T, Okutsu H, Ohtake A, Sasamata M, Matsukawa Y, Funahashi Y, Kato M, Hattori R, Gotoh M. Effect of tamsulosin on bladder microcirculation in a rat ischemiareperfusion model, evaluated by pencil lens charge-coupled device microscopy system. Urology 2010; 76: 1266.e1-1266.e5.
Nakazawa M, Taguchi Y, Yang XP, Chiba S. The functional alpha-adrenoceptor in dog caudal vesical arteries is mainly an α1A subtype. Auton Autacoid Pharmacol 2002; 22: 253-259.
Nasu K, Moriyama N, Kawabe K, Tsujimoto G, Murai M, Tanaka T, Yano J. Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol 1996; 119: 797-803.
Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of α1 and βadrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol 2003; 170: 649-653.
Nomiya M, Yamaguchi O, Andersson KE, Sagawa K, Aikawa K, Shishido K, Yanagida T, Kushida N, Yazaki J, Takahashi N. The effect of atherosclerosis-induced chronic bladder ischemia on bladder function in the rat. Neurourol Urodyn 2012; 31: 195-200.
Ohtake A, Ukai M, Saitoh C, Sonoda R, Noguchi Y, Okutsu H, Yuyama H, Sato S, Sasamata M, Miyata K. Effect of tamsulosin on spontaneous bladder contraction in conscious rats with bladder outlet obstruction: comparison with effect on intraurethral pressure. Eur J Pharmacol 2006; 545: 185-191.
Peters TJ, Donovan JL, Kay HE, Abrams P, de la Rosette JJ, Porru D, Thüroff JW. The International Continence Society “Benign Prostatic Hyperplasia” Study: the bothersomeness of urinary symptoms. J Urol 1997; 157: 885-889.
Pinggera GM, Mitterberger M, Pallwein L, Schuster A, Herwig R, Frauscher F, Bartsch G, Strasser H. α-Blockers improve chronic ischaemia of the lower urinary tract in patients with lower urinary tract symptoms. BJU Int 2008a; 101: 319-324.
Pinggera GM, Mitterberger M, Steiner E, Pallwein L, Frauscher F, Aigner F, Bartsch G, Strasser H. Association of lower urinary tract symptoms and chronic ischaemia of the lower urinary tract in elderly women and men: assessment using colour Doppler ultrasonography. BJU Int 2008b; 102: 470-474.
Ponholzer A, Temml C, Wehrberger C, Marszalek M, Madersbacher S. The association between vascular risk factors and lower urinary tract symptoms in both sexes. Eur Urol 2006; 50: 581-586.
Poulsen AL, Schon J, Puggaard L, Torp-pedersen S, Nording J. Prostatic enlargement, symptomatology and pressure/flow evaluation: interrelations in patients with symptomatic BPH. Scand J Urol Nephrol Suppl 1994; 157: 67-73.
Rollema HJ, Mastrigt RV. Improved indication and follow-up in transurethral resection of the prostate using the computer program CLIM: A prospective study. J Urol 1992; 148: 111-115.
Sagnier PP, Girman CJ, Garraway M, Kumamoto Y, Lieber MM, Richard F, MacFarlane G, Guess HA, Jacobsen SJ, Tsukamoto T, Boyle P. International comparison of the community prevalence of symptoms of prostatism in four countries. Eur Urol 1996; 29: 15-20.
Sato S, Hatanaka T, Yuyama H, Ukai M, Noguchi Y, Ohtake A, Taguchi K, Sasamata M, Miyata K. Tamsulosin potently and selectively antagonizes human recombinant α(1A/1D)- adrenoceptors: slow dissociation from the α(1A)-adrenoceptor may account for selectivity for α(1A)-adrenoceptor over α(1B)-adrenoceptor subtype. Biol Pharm Bull 2012; 35: 72-77.
Seki N, Takahashi R, Yamaguchi A, Ito K, Takayama K, Nanri K, Kamiryo Y, Yamashita H, Komine S, Miyazaki Y, Uozumi J, Naito S. Non-inferiority of silodosin 4 mg once daily to twice daily for storage symptoms score evaluated by the International Prostate
Symptom Score in Japanese patients with benign prostatic hyperplasia: A multicenter, randomized, parallel-group study. Int J Urol 2015; 22: 311-316.
Smith KM, Macmillan JB, McGrath JC. Investigation of a1-adrenoceptor subtypes mediating vasoconstriction in rabbit cutaneous resistance arteries. Br J Pharmacol 1997; 122: 825-832.
Tai HC, Chung SD, Ho CH, Tai TY, Yang WS, Tseng CH, Wu HP, Yu HJ. Metabolic syndrome components worsen lower urinary tract symptoms in women with type 2 diabetes. J Clin Endocrinol Metab 2010; 95: 1143-1150.
Tanuma Y, Tanaka Y, Takeyama K, Okamoto T. The predictive factors of α1-D/A adrenoceptor antagonist, naftopidil, dose increase therapy for male lower urinary tract symptoms caused by benign prostatic hyperplasia: INFORM study. Urol Ann 2017; 9: 261-267.
Ukai M, Yuyama H, Noguchi Y, Someya A, Okutsu H, Watanabe M, Yoshino T, Ohtake A, Suzuki M, Sato S, Sasamata M. Participation of endogenous endothelin and ETA receptor in premicturition contractions in rats with bladder outlet obstruction. NaunynSchmiedeberg’s Arch Pharmacol 2006; 373: 197-203.
Yu HJ, Chien CT, Lai YJ, Lai MK, Chen CF, Levin RM, Hsu SM. Hypoxia preconditioning attenuates bladder overdistension-induced oxidative injury by up-regulation of Bcl-2 in the rat. J Physiol 2004; 554: 815-828.
Zhang HL, Huang ZG, Qiu Y, Cheng X, Zou XQ, Liu TT. Tamsulosin for treatment of lowerurinary tract symptoms in women: a systematic review and meta-analysis. Int J Impot Res 2017; 29: 148-156.
Zhang X, Igawa Y, Ishizuka O, Nishizawa O, Andersson KE. Effects of resiniferatoxin desensitization of capsaicin-sensitive afferents on detrusor over-activity induced by intravesical capsaicin, acetic acid or ATP in conscious rats. Naunyn Schmiedebergs Arch Pharmacol. 2003; 367: 473-479.
日本新薬株式会社 エビプロスタット®錠 医薬品インタビューフォーム
LTLファーマ株式会社 日本薬局方アモスラロール塩酸塩錠 ローガン錠®10 mg 医薬品インタビューフォーム
厚生労働省大臣官房統計情報部 平成26年 患者調査 (傷病分類編)
竹中登一、藤倉峻、本田一男、浅野雅晴、新形邦宏 新規α1受容体遮断薬、塩酸タムスロシン塩酸塩の研究開発 薬学雑誌、1995; 115: 773-789.
竹中登一 前立腺肥大症に伴う排尿障害治療薬タムスロシン塩酸塩(ハルナール®)の創薬 医学のあゆみ、2015; 252: 323-325.
日本泌尿器科学会編 男性下部尿路症状・前立腺肥大症診断ガイドライン
吉田正貴、永田卓士、桝永浩一、宮本豊、工藤惇三 過活動膀胱の病態と薬物治療 臨床薬理、2009; 40: 201-206.